Published in:
06-05-2024 | Attention Deficit Hyperactivity Disorder | Adis Summary of Research
Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
Published in: Drugs & Therapy Perspectives | Issue 4/2024
Login to get accessAbstract
In patients with attention deficit hyperactivity disorder (ADHD), norepinephrine reuptake inhibitors like atomoxetine may show mild effectiveness in addressing both inattention and hyperactivity/impulsivity. The relative efficacy of branded extended-release viloxazine (viloxazine ER) compared to generic atomoxetine remains unknown. This Adis Summary of Research summarizes the efficacy and tolerability of a voluntary switch from atomoxetine to viloxazine ER, prompted by adverse events or inadequate response, based on a retrospective chart review conducted in the USA. The switch improved ADHD symptoms and tolerability.